| 1517 |
National Cancer Institute |
Html |
en |
Pancreatic Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pancreatic cancer. |
| cancer treatment | 0.45958 |
| malignant tumor cells | 0.419406 |
| body | 0.510954 |
| chemotherapy | 0.404222 |
| PDQ cancer information | 0.497348 |
| clinical trial search | 0.455776 |
| pancreas | 0.487969 |
| clinical trials | 0.753194 |
| nearby lymph nodes | 0.471943 |
| cancer information summary | 0.460465 |
| clinical trial | 0.646358 |
| cancer cells | 0.504208 |
| exocrine pancreatic cancer | 0.466193 |
| patients | 0.395936 |
| treatment clinical trial | 0.39568 |
| endocrine pancreatic cancer | 0.462275 |
| NCI PDQ cancer | 0.417319 |
| Pancreatic Cancer Treatment | 0.455234 |
| Treatment Editorial Board | 0.392271 |
| small intestine | 0.597674 |
| endocrine pancreas cells | 0.397632 |
| general cancer information | 0.404462 |
| treatment | 0.608368 |
| general information | 0.413544 |
| new cancer treatments | 0.400431 |
|
| NCI-supported cancer | 0.412236 |
| Cancer Information Service | 0.405331 |
| specific cancer cells | 0.402178 |
| pancreatic cancer | 0.933074 |
| pancreatic cancer spreads | 0.442487 |
| stage pancreatic cancer | 0.467555 |
| treatment clinical trials | 0.430898 |
| National Cancer Institute | 0.509295 |
| Pancreatic Neuroendocrine Tumors | 0.405468 |
| new treatment | 0.444026 |
| Radiation therapy | 0.523817 |
| Blood. The cancer | 0.396713 |
| PDQ summary | 0.454317 |
| cancer research process | 0.390975 |
| cancer clinical trials | 0.486763 |
| tumor | 0.448545 |
| high-energy sound waves | 0.434518 |
| cancer information summaries | 0.402821 |
| comprehensive cancer information | 0.402789 |
| internal radiation therapy | 0.390099 |
| cancer | 0.947965 |
| information | 0.519314 |
| standard treatment | 0.39251 |
| Recurrent pancreatic cancer | 0.47605 |
|
CLICK HERE |
| 1562 |
National Cancer Institute |
Html |
en |
Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of hypopharyngeal cancer. |
| cancer treatment | 0.321266 |
| high-dose radiation therapy | 0.323579 |
| centimeters | 0.269921 |
| cancer spreads | 0.270417 |
| malignant tumor cells | 0.281954 |
| body | 0.305644 |
| chemotherapy | 0.290118 |
| PDQ cancer information | 0.346817 |
| stage III hypopharyngeal | 0.274417 |
| clinical trial search | 0.347149 |
| clinical trials | 0.698171 |
| hypopharynx | 0.280224 |
| cancer information summary | 0.319294 |
| metastatic hypopharyngeal cancer | 0.310093 |
| clinical trial | 0.551798 |
| Recurrent hypopharyngeal cancer | 0.306668 |
| patients | 0.317052 |
| stage IV hypopharyngeal | 0.274937 |
| nearby soft tissue | 0.271159 |
| treatment clinical trial | 0.275593 |
| NCI PDQ cancer | 0.283768 |
| radiation therapy | 0.705932 |
| Treatment Editorial Board | 0.281401 |
| General information | 0.289657 |
| hypopharyngeal cancer | 0.722179 |
|
| general cancer information | 0.275426 |
| treatment | 0.442202 |
| new cancer treatments | 0.272872 |
| NCI-supported cancer | 0.296123 |
| cancer cells | 0.361641 |
| Cancer Information Service | 0.276024 |
| patient | 0.26688 |
| lymph nodes | 0.350794 |
| treatment clinical trials | 0.300384 |
| National Cancer Institute | 0.364736 |
| swollen lymph nodes | 0.277694 |
| new treatment | 0.302418 |
| External radiation therapy | 0.314938 |
| neck | 0.309398 |
| cancer research process | 0.269057 |
| cancer clinical trials | 0.358746 |
| stage | 0.310003 |
| neck cancer | 0.286172 |
| lymph node | 0.322344 |
| cancer information summaries | 0.27414 |
| comprehensive cancer information | 0.274558 |
| cancer | 0.901171 |
| standard treatment | 0.274055 |
| Hypopharyngeal Cancer Treatment | 0.314822 |
|
CLICK HERE |
| 1621 |
National Cancer Institute |
Html |
en |
Ewing Sarcoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of Ewing sarcoma. |
| cancer treatment | 0.289749 |
| malignant tumor cells | 0.276208 |
| soft tissue | 0.253817 |
| body | 0.332426 |
| type | 0.219713 |
| chemotherapy | 0.237331 |
| treatments | 0.202586 |
| PDQ cancer information | 0.292839 |
| clinical trial search | 0.246556 |
| extraosseous Ewing sarcoma | 0.264218 |
| Ewing sarcoma spreads | 0.243807 |
| clinical trials | 0.704097 |
| Pediatric Treatment Editorial | 0.209616 |
| nearby lymph nodes | 0.208892 |
| cancer information summary | 0.25517 |
| clinical trial | 0.374839 |
| recurrent Ewing sarcoma | 0.335434 |
| stage Ewing sarcoma | 0.262403 |
| patients | 0.209976 |
| Soft Tissue Sarcoma | 0.20334 |
| childhood Ewing sarcoma | 0.227663 |
| CAR T-cell therapy | 0.238653 |
| NCI PDQ cancer | 0.207565 |
| Ewing sarcoma family | 0.264166 |
| radiation therapy | 0.525383 |
|
| Treatment Editorial Board | 0.214583 |
| treatment | 0.586815 |
| Ewing sarcoma | 0.925686 |
| Ewing sarcoma cells | 0.277555 |
| NCI-supported cancer | 0.206887 |
| cancer cells | 0.457951 |
| metastatic Ewing sarcoma | 0.365401 |
| specific cancer cells | 0.219988 |
| patient | 0.217481 |
| treatment clinical trials | 0.236708 |
| National Cancer Institute | 0.256904 |
| initial treatment | 0.212474 |
| effects cancer treatment | 0.221598 |
| new treatment | 0.271508 |
| bone | 0.246041 |
| metastatic tumor | 0.210193 |
| bone marrow | 0.235686 |
| Ewing tumor | 0.226375 |
| cancer clinical trials | 0.279951 |
| stem cell rescue | 0.32512 |
| tumor | 0.434783 |
| High-dose chemotherapy | 0.218893 |
| cancer | 0.820936 |
| standard treatment | 0.227171 |
|
CLICK HERE |
| 1664 |
National Cancer Institute |
Html |
en |
Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood atypical teratoid/rhabdoid tumors |
| cancer treatment | 0.542006 |
| metastatic brain tumors | 0.391418 |
| ongoing clinical trials | 0.389415 |
| PDQ cancer information | 0.511527 |
| tumor suppressor genes | 0.452709 |
| clinical trial search | 0.399694 |
| brain tumors | 0.444671 |
| CNS atypical teratoid/rhabdoid | 0.388691 |
| clinical trials | 0.847224 |
| Pediatric Treatment Editorial | 0.416481 |
| Teratoid/Rhabdoid Tumor Treatment | 0.445097 |
| cancer information summary | 0.463674 |
| clinical trial | 0.521041 |
| cancer cells | 0.510172 |
| stem cell transplant | 0.396934 |
| patients | 0.411179 |
| primary brain tumors | 0.3918 |
| treatment clinical trial | 0.409064 |
| NCI PDQ cancer | 0.42324 |
| radiation therapy | 0.555658 |
| Treatment Editorial Board | 0.420841 |
| Cord Tumors Treatment | 0.414346 |
| late effects | 0.393798 |
| treatment | 0.689522 |
| new cancer treatments | 0.395428 |
|
| PDQ treatment summary | 0.447943 |
| childhood brain | 0.385451 |
| Cancer Information Service | 0.399251 |
| specific cancer cells | 0.397642 |
| PDQ Pediatric Treatment | 0.40786 |
| treatment clinical trials | 0.444124 |
| National Cancer Institute | 0.458723 |
| spinal cord | 0.616147 |
| tumor cells | 0.437516 |
| effects cancer treatment | 0.421518 |
| new treatment | 0.427513 |
| childhood cancer information | 0.400212 |
| External radiation therapy | 0.395094 |
| brain tumor | 0.405279 |
| brain | 0.467984 |
| atypical teratoid/rhabdoid tumor | 0.982554 |
| PDQ summary | 0.439127 |
| cancer clinical trials | 0.434177 |
| cancer information summaries | 0.39809 |
| comprehensive cancer information | 0.397631 |
| cancer | 0.740574 |
| appropriate cancer treatment | 0.419383 |
| standard treatment | 0.391688 |
| fast-growing tumor | 0.388774 |
|
CLICK HERE |
| 1718 |
National Cancer Institute |
Html |
en |
Pap and HPV Testing |
A fact sheet that describes the Pap and HPV tests, possible results from those tests, and the link between HPV and cervical cancer. |
| Pap test results | 0.318639 |
| precancerous cervical lesions | 0.292159 |
| squamous cells | 0.289348 |
| high-risk HPV | 0.671741 |
| First-line HPV testing | 0.290741 |
| squamous cell abnormalities | 0.296427 |
| primary HPV screening | 0.318981 |
| cervical screening | 0.408649 |
| glandular cell abnormalities | 0.323902 |
| professional cervical cancer | 0.287037 |
| cervical cells | 0.449089 |
| Pap test | 0.978312 |
| HPV testing | 0.403472 |
| frequent cervical screening | 0.280097 |
| cell abnormalities | 0.445026 |
| HPV test | 0.442688 |
| negative HPV test | 0.307642 |
| cervical cancer screening | 0.819575 |
| positive HPV test | 0.337496 |
| cervical cancer | 0.958343 |
| HPV DNA test | 0.30151 |
| Pap cytology test | 0.279358 |
| early cervical cancers | 0.308324 |
| HPV infections | 0.362202 |
|
| HPV test results | 0.327074 |
| abnormal cells | 0.314778 |
| abnormal cervical cells | 0.343301 |
| precancerous cervical lesion | 0.309268 |
| HPV | 0.765136 |
| Pap test result | 0.433853 |
| different HPV tests | 0.296834 |
| cervical cell abnormalities | 0.361261 |
| cobas HPV test | 0.304363 |
| high-risk HPV types | 0.661339 |
| additional high-risk HPV | 0.303577 |
| new cervical cancers | 0.27692 |
| high-risk HPV type | 0.405337 |
| cervical cancer risk | 0.324311 |
| HPV cotesting | 0.335213 |
| liquid-based Pap cytology | 0.286767 |
| future cervical cancer | 0.287194 |
| abnormal Pap test | 0.300522 |
| HPV infection | 0.371378 |
| cells | 0.464647 |
| regular cervical screening | 0.330087 |
| Routine cervical screening | 0.314661 |
| Pap testing | 0.293059 |
| cell changes | 0.293167 |
|
CLICK HERE |
| 1883 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores extracraneales de células germinativas en la niñez (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores extracraneales de células germinativas en la niñez. |
| cell tumor protocols | 0.408279 |
| germinativas malignas localización | 0.405353 |
| células germinativas seminomatosos.Seminoma | 0.410393 |
| cell tumor combined | 0.407867 |
| germ cell tumours | 0.412186 |
| Perlman EJ | 0.405253 |
| Calaminus G | 0.412513 |
| Cell Cancer Collaborative | 0.406794 |
| cell tumors from | 0.406747 |
| Göbel U | 0.406021 |
| Cancer Group | 0.42074 |
| cell tumor studies | 0.407558 |
| pediatric oncology | 0.41388 |
| células germinativas mixtos | 0.417539 |
| International Germ Cell | 0.417008 |
| Children's Oncology Group | 0.409014 |
| mediastinal germ | 0.406328 |
| cell tumor study | 0.408368 |
| <2 cm | 0.405406 |
| Metástasis peritoneales macroscópicas | 0.405941 |
| germ cell neoplasms | 0.406391 |
| Children's Cancer | 0.42175 |
| cell tumors show | 0.406094 |
| pediatric germ | 0.426106 |
| adultos jóvenes | 0.40725 |
|
| estadio iv | 0.405826 |
| ganglios linfáticos ≥2 | 0.411723 |
| Germ Cell Consensus | 0.412507 |
| Cushing B | 0.405386 |
| teratomas benignos | 0.407141 |
| Genes Chromosomes Cancer | 0.438953 |
| with germ | 0.406335 |
| malignant germ cell | 0.462527 |
| PDQ Tratamiento | 0.405882 |
| childhood germ | 0.409831 |
| cell tumors based | 0.405903 |
| Clin Oncol | 0.444548 |
| saco vitelino | 0.435575 |
| linfáticos ≥2 cm | 0.408554 |
| Schneider DT | 0.409517 |
| Children's Cancer Group | 0.419331 |
| Cell Consensus Classification | 0.409901 |
| germ cell tumors | 0.974328 |
| Kingdom Children Cancer | 0.408316 |
| germ cell cancer | 0.410294 |
| Children's Cancer Study | 0.409136 |
| pediatric oncology group | 0.410202 |
| oncology group | 0.420408 |
| Cancer Study Group | 0.411644 |
|
CLICK HERE |
| 2000 |
National Cancer Institute |
Html |
es |
Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la histiocitosis de células de Langerhans. |
| cuánto aire | 0.415134 |
| siguientes procedimientos | 0.528715 |
| células madre | 0.858073 |
| adultos jóvenes | 0.464664 |
| efectos secundarios meses | 0.439126 |
| siguientes aspectos | 0.434701 |
| faja ajustadora | 0.428231 |
| HCL infantil multisistémica | 0.546722 |
| cuántos sistemas | 0.518567 |
| genes ras | 0.453948 |
| pequeña cantidad | 0.423844 |
| células normales.ampliar exploración | 0.532323 |
| vÃa oral | 0.42013 |
| rayos x | 0.425227 |
| gen braf | 0.666188 |
| largo plazo | 0.44968 |
| cuántas células | 0.518957 |
| niño ayuda | 0.426203 |
| efectos tardÃos | 0.516221 |
| escáner.ampliar exploración | 0.429231 |
| tarde.ampliar ecografÃa | 0.427113 |
|
| vÃas respiratorias | 0.424871 |
| causa problemas | 0.424997 |
| lesiones óseas | 0.423193 |
| National Cancer Institute | 0.417904 |
| IRMN).Ampliar Imágenes | 0.421648 |
| siguientes riesgos | 0.415861 |
| radiación uvb | 0.414555 |
| Instituto Nacional | 0.431398 |
| PDQ Tratamiento | 0.451873 |
| antecedentes familiares | 0.589915 |
| llamada genes ras | 0.432872 |
| explorador tep | 0.430081 |
| terapia fotodinámica causa | 0.453098 |
| sistema nervioso central | 0.604707 |
| Physician Data Query | 0.464236 |
| mayores probabilidades | 0.416225 |
| HCL multisistémica | 0.966875 |
| terapia fotodinámica llamada | 0.451949 |
| radiación ultravioleta | 0.561342 |
| siguientes pruebas | 0.489919 |
|
CLICK HERE |
| 3438 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de estómago (gástrico) (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de estómago (gástrico). |
| Offerhaus J | 0.113586 |
| Cancer Res Clin | 0.264444 |
| Cancer high-risk subjects | 0.263357 |
| mass screening | 0.365942 |
| Leung WK | 0.124317 |
| Kobayashi K | 0.11932 |
| American Cancer Society | 0.823817 |
| detección versus | 0.189954 |
| case-control study | 0.112022 |
| Tytgat GN | 0.125733 |
| CA Cancer | 0.258236 |
| Instituto Nacional | 0.144846 |
| PDQ Exámenes | 0.215492 |
| prospectively followed chinese | 0.229607 |
| Estados Unidos | 0.202827 |
| Yanaoka K | 0.108053 |
| biological agents | 0.104643 |
| Morson BC | 0.118473 |
| high risk | 0.121936 |
| repeated endoscopic screens | 0.228776 |
| Lancet Oncol | 0.24929 |
| mass screening program | 0.337333 |
| mass survey | 0.121584 |
| Gastrointestinal Tract | 0.130066 |
| Ma JL | 0.109737 |
|
| mass screening techniques | 0.150063 |
| Precancerous Lesions | 0.123357 |
| Barbara L | 0.103989 |
| Cancer Facts | 0.263557 |
| Pfeiffer R | 0.11257 |
| Costa Rica | 0.0971337 |
| detección darán | 0.220411 |
| Mathus-Vliegen EM | 0.121366 |
| Ubukata T | 0.120185 |
| National Cancer Institute | 0.793771 |
| Oka M | 0.099234 |
| gastric carcinoma | 0.217462 |
| Endoscopic screening during | 0.138672 |
| serum pepsinogen concentrations | 0.241325 |
| New York | 0.185957 |
| Clin Oncol | 0.132653 |
| Kitahara F | 0.112823 |
| Sherlock P | 0.239085 |
| X-ray screening seems | 0.130764 |
| serum pepsinogen | 0.612986 |
| using serum pepsinogen | 0.482271 |
| Sato T | 0.127922 |
| stomach cancer | 0.944477 |
| Wu MS | 0.109301 |
|
CLICK HERE |
| 15640 |
National Cancer Institute |
Html |
null |
Research & Development (R&D) Contracts |
null |
|
|
CLICK HERE |
| 16683 |
National Cancer Institute |
Html |
es |
714-X (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso del 714-X como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Alternative Medicine Confronts | 0.349 |
| Task Force | 0.681834 |
| Rock Forest | 0.4465 |
| Cancer Research Initiative | 0.920081 |
| Radiosensitizing effect | 0.323708 |
| but not | 0.32369 |
| Goel HC | 0.323157 |
| Alternative Therapeutic | 0.727518 |
| Bacteria Cause Cancer | 0.362108 |
| Unconventional therapies | 0.71198 |
| Breast Cancer Research | 0.913503 |
| saccharin-LiCl conditioned stimulus | 0.34146 |
| Roa AR | 0.322774 |
| transplantable mammary | 0.323668 |
| Instituto Nacional | 0.49296 |
| Pharmacol Biochem Behav | 0.342417 |
| Pavlovian conditioning | 0.324132 |
| PDQ 714-X | 0.384196 |
| posibles efectos | 0.32412 |
| Estados Unidos | 0.547224 |
| Canadian Breast Cancer | 0.923206 |
| for bacteria as | 0.342644 |
| vÃa nasal | 0.324957 |
| Purohit A | 0.322533 |
| New York University | 0.333776 |
|
| alcanfor mejora | 0.352671 |
| Conditioned enhancement | 0.324112 |
| linfoma caninos | 0.323743 |
| CERBE Distribution | 0.468077 |
| Solvason HB | 0.367895 |
| Hiramoto RN | 0.325133 |
| new approach | 0.322794 |
| empresa distribuidora | 0.324674 |
| National Cancer Institute | 0.431242 |
| Hiramoto NS | 0.502986 |
| vitamina b12 | 0.324597 |
| New York | 0.3535 |
| accessed april | 0.467486 |
| Neurosci Res | 0.325453 |
| numerosos oligoelementos | 0.325391 |
| Physician Data Query | 0.337084 |
| Hess DJ | 0.368799 |
| libre uso | 0.325033 |
| linfosarcoma murinos | 0.323938 |
| Ghanta VK | 0.432317 |
| cartÃlago bovino | 0.325426 |
| killer cell activity | 0.342736 |
| response to yc8 | 0.339588 |
| Soong SJ | 0.323559 |
|
CLICK HERE |